Congratulations to our 2nd class of Seres Scholars from CRLS! We’re #SeresProud to continue this partnership to promote #DEI in education, as we offer #mentorship, guidance, and opportunities for underserved students from our community.

We’re #SeresProud to celebrate the 1st anniversary of the opening of our Quality Control Center of Excellence. Located in Waltham, MA, the center is continuing our work to revolutionize #microbiome therapeutics & transform the lives of patients with unmet needs. Cheers to 1 year!

We’re #SeresProud to announce the publication of our Literature Review Manuscript in Infectious Disease and Therapy. Read more about #Cdiff patient experiences: bit.ly/3K204we

Our Greater Boston area teams are #SeresProud to volunteer with Circle of Hope, Inc. to create and donate 500 dignity bags of hygiene essentials & 600 COVID kits to help underserved communities stay healthy and safe. Thank you Life Science Cares Boston for helping organize this event!

Join Seres today at 8:30 AM EDT for the presentation of our Q2 2023 financial results and operational progress. Join the webcast: ir.serestherapeutics.com/events/event-d…

Alongside our collaborator, Nestle Health Science, we are executing the launch our oral microbiome therapy in the United States. In today’s Q2 2023 earnings report, we were pleased to announce highly encouraging initial launch results.

Join our presentation today at 3 PM EDT at Canaccord Genuity’s 43rd Annual Growth Conference. Can’t make it? An audio webcast will be available on our website: ir.serestherapeutics.com/news-releases/…

We’re on a mission to revolutionize #microbiome therapeutics. This summer, all of our teams came together to collaborate on achieving our goals to better serve patients and celebrate our progress to date. We couldn’t be more #SeresProud of our team!

Antimicrobial resistance (#AMR) is one of our greatest public health threats, and the situation is worsening. In STAT we explain why innovative #microbiome therapeutic options may be important for combating antibiotic resistance: bit.ly/3YwVP1w

Can new advancements in #microbiome therapeutics change how we fight anti-microbial resistance (#AMR)? Join Seres’ Chief Scientific Officer Matthew Henn (Matthew Henn) & team at World Antimicrobial Resistance Congress to discuss potential solutions. See details: bit.ly/45pSoMt #WorldAMRCongress

We’re #SeresProud to celebrate the grand opening of our new CLIA lab with a ribbon-cutting ceremony in Lower Gwynedd, Pa. This new donor screening facility will allow us to continue our mission to transform patients’ lives by revolutionizing #microbiome therapeutics.

Attention #FierceNPP attendees! Join our Chief Commercial & Strategy Officer Terri Young today at 9:00AM ET to hear insights and best practices drawn from her experience. #SeresProud Fierce Life Sciences Events

At Seres, we have been pioneering the development of microbiome therapeutics since 2011. As a #FlagshipFounded company, we took bold leaps in 2023 to transform the lives of patients as we received FDA approval for the first orally administered microbiome-based therapeutic. We're

We are excited to present at #TANDEM24 in San Antonio. Join us at the poster session on Feb 22nd at 6:45pm CST to learn about preliminary data from our currently enrolling Phase 1b study of investigational #microbiome therapeutic SER-155. Learn more: tandem.confex.com/tandem/2024/me…

Seres has completed enrollment for Cohort 2 of the Phase 1b clinical trial of SER-155 in Allo #HSCT patients, bringing us closer to potentially revolutionizing the approach to enteric-derived and bloodstream infections post-transplantation. ir.serestherapeutics.com/news-releases/…

Seres is excited to present new preliminary data on investigational #microbiome therapeutic SER-155 from the first cohort (open-label) of our Phase 1b study in hematopoietic stem cell transplant patients at #ASCO24 in Chicago. Join us at the poster session on June 3rd at 9am

Today, we entered into an agreement w/ partner NestleHealthScience to acquire Vowst, a deal that allows us to focus on our pioneering mission of advancing revolutionary microbiome therapeutics for as many patients as possible. ir.serestherapeutics.com/news-releases/…

Our team had a great time at Friday’s #BioBall event, sponsored by Special Olympics Massachusetts. Not only was it fun to get together, but we helped raise money to support our local #SpecialOlympics athletes! Learn more about the cause:  fundraise.specialolympicsma.org/index.cfm?fuse…

Today we're excited to announce that we've signed the VOWST asset purchase agreement with Nestlé. The completion of the transaction, which is subject to Seres’ shareholder approval and other customary conditions, is expected to occur in the next 90 days. Read the full release:

Today we’re pleased to share Cohort 2 data from our Phase 1b study evaluating SER-155 in patients undergoing allo-HSCT. Read the full release: ir.serestherapeutics.com/news-releases/…